Filed revenue acceleration
Active · now 13.46%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
INDV Indivior Pharmaceuticals Inc
Healthcare
32.45
Close 10/16
- P/E
- 11.6
52W 23.72 42.81
Loading candles…
Is Indivior Pharmaceuticals Inc a buy? Fundamentals and valuation first
As of 2026-10-16
Valuation: Fair, Growth: Good, Risk / liquidity: Good; Quality: Weak.
Valuation Fair TTM P/E is Fair, but Free-cash-flow yield is Average.
TTM P/E 11.63 27th percentile Fair
Price / book -18.41 N/A
Free-cash-flow yield (%) -2.9 34th percentile Average
Quality Weak Operating margin, TTM is Top, but ROE, TTM is Lagging.
ROE, TTM (%) -170.67 7th percentile Lagging
Operating margin, TTM (%) 34.68 86th percentile Top
FCF margin, TTM (%) -8.33 26th percentile Average
Growth Good Diluted EPS growth, TTM YoY is Top; Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 13.46 67th percentile Good
Diluted EPS growth, TTM YoY (%) 179 89th percentile Top
Momentum Neutral 240-day return is Good, but 60-day return is Average.
60-day return (%) -19.9 26th percentile Average
240-day return (%) 10.49 65th percentile Good
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 71,318,831 85th percentile Top
60-day annualized volatility (%) 30.32 34th percentile Good
Indivior Pharmaceuticals Inc (INDV) peers and tracking
Watchlist
This page refreshes daily after the close. Add Indivior Pharmaceuticals Inc to your watchlist to track signal changes on your next visit.
Indivior Pharmaceuticals Inc (INDV) quant signal backtests
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
More history: Market-wide momentum baseline, Signals not active now
Market-wide momentum baseline
Across 98,524 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.48%, a 58.4% positive-return rate, and +3.13 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
52-week adjusted-price high
PendingAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
19 times historically; 60-day forward avg +3.53%, win rate 42.1%, beating the market by +1.16 pts on average.
Top-quintile 6-month momentum
PendingThe stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
23 times historically; 60-day forward avg +16.02%, win rate 65.2%, beating the market by +9.62 pts on average.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
11 times historically; 60-day forward avg +7.31%, win rate 60%, beating the market by +1.12 pts on average.
Continue researching Indivior Pharmaceuticals Inc with the evidence above.
Continue in Studio ↗Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.